Literature DB >> 16364913

Cell motility is controlled by SF2/ASF through alternative splicing of the Ron protooncogene.

Claudia Ghigna1, Silvia Giordano, Haihong Shen, Federica Benvenuto, Fabio Castiglioni, Paolo Maria Comoglio, Michael R Green, Silvano Riva, Giuseppe Biamonti.   

Abstract

Ron, the tyrosine kinase receptor for the Macrophage-stimulating protein, is involved in cell dissociation, motility, and matrix invasion. DeltaRon, a constitutively active isoform that confers increased motility to expressing cells, is generated through the skipping of exon 11. We show that abnormal accumulation of DeltaRon mRNA occurs in breast and colon tumors. Skipping of exon 11 is controlled by a silencer and an enhancer of splicing located in the constitutive exon 12. The strength of the enhancer parallels the relative abundance of DeltaRon mRNA and depends on a sequence directly bound by splicing factor SF2/ASF. Overexpression and RNAi experiments demonstrate that SF2/ASF, by controlling the production of DeltaRon, activates epithelial to mesenchymal transition leading to cell locomotion. The effect of SF2/ASF overexpression is reverted by specific knockdown of DeltaRon mRNA. This demonstrates a direct link between SF2/ASF-regulated splicing and cell motility, an activity important for embryogenesis, tissue formation, and tumor metastasis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16364913     DOI: 10.1016/j.molcel.2005.10.026

Source DB:  PubMed          Journal:  Mol Cell        ISSN: 1097-2765            Impact factor:   17.970


  191 in total

Review 1.  The pathogenicity of splicing defects: mechanistic insights into pre-mRNA processing inform novel therapeutic approaches.

Authors:  Elisabeth Daguenet; Gwendal Dujardin; Juan Valcárcel
Journal:  EMBO Rep       Date:  2015-11-13       Impact factor: 8.807

Review 2.  The RNAissance family: SR proteins as multifaceted regulators of gene expression.

Authors:  Jonathan M Howard; Jeremy R Sanford
Journal:  Wiley Interdiscip Rev RNA       Date:  2014-08-22       Impact factor: 9.957

3.  Loss of exon identity is a common mechanism of human inherited disease.

Authors:  Timothy Sterne-Weiler; Jonathan Howard; Matthew Mort; David N Cooper; Jeremy R Sanford
Journal:  Genome Res       Date:  2011-07-12       Impact factor: 9.043

4.  Alternative splicing as a therapeutic target for human diseases.

Authors:  Kenneth J Dery; Veronica Gusti; Shikha Gaur; John E Shively; Yun Yen; Rajesh K Gaur
Journal:  Methods Mol Biol       Date:  2009

Review 5.  Aberrant RNA splicing and its functional consequences in cancer cells.

Authors:  James D Fackenthal; Lucy A Godley
Journal:  Dis Model Mech       Date:  2008 Jul-Aug       Impact factor: 5.758

Review 6.  Biologic and clinical significance of androgen receptor variants in castration resistant prostate cancer.

Authors:  Kathryn E Ware; Mariano A Garcia-Blanco; Andrew J Armstrong; Scott M Dehm
Journal:  Endocr Relat Cancer       Date:  2014-05-23       Impact factor: 5.678

Review 7.  TGF-beta signaling in cancer: post-transcriptional regulation of EMT via hnRNP E1.

Authors:  Breege V Howley; Philip H Howe
Journal:  Cytokine       Date:  2018-02-01       Impact factor: 3.861

8.  Splicing factor SRSF1 promotes gliomagenesis via oncogenic splice-switching of MYO1B.

Authors:  Xuexia Zhou; Run Wang; Xuebing Li; Lin Yu; Dan Hua; Cuiyun Sun; Cuijuan Shi; Wenjun Luo; Chun Rao; Zhendong Jiang; Ying Feng; Qian Wang; Shizhu Yu
Journal:  J Clin Invest       Date:  2019-01-14       Impact factor: 14.808

Review 9.  Alternative splicing and disease.

Authors:  Jamal Tazi; Nadia Bakkour; Stefan Stamm
Journal:  Biochim Biophys Acta       Date:  2008-10-17

10.  Cancer-associated regulation of alternative splicing.

Authors:  Julian P Venables; Roscoe Klinck; ChuShin Koh; Julien Gervais-Bird; Anne Bramard; Lyna Inkel; Mathieu Durand; Sonia Couture; Ulrike Froehlich; Elvy Lapointe; Jean-François Lucier; Philippe Thibault; Claudine Rancourt; Karine Tremblay; Panagiotis Prinos; Benoit Chabot; Sherif Abou Elela
Journal:  Nat Struct Mol Biol       Date:  2009-05-17       Impact factor: 15.369

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.